

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO. ALLIA.143CP3	APPLICATION NO. 09/873,901
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (USE SEVERAL SHEETS IF NECESSARY)		APPLICANT Habib Zaghouani	
		FILING DATE June 4, 2001	GROUP 1644

RECEIVED
FEB 11 2002
TECH CENTER 1600/2900

U.S. PATENT DOCUMENTS						
EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE (IF APPROPRIATE)
1	5,969,109	10/19/99	Bona, et al.			

FOREIGN PATENT DOCUMENTS							
EXAMINER INITIAL	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO
PN	2 WO 98/10584	06/27/98	PCT				
PN	3 WO 99/09064	02/25/99	PCT				
PN	4 WO 00/01732	01/13/00	PCT				

EXAMINER INITIAL	OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)	
PN	5 ✓	Adorini, et al., New Perspectives on Immunointervention in Autoimmune Diseases, <i>Immunol. Today</i> , 11(11):383-386 (1990).
	6 ✓	Cullen, et al., A Divalent Major Histocompatibility Complex/IgG1 Fusion Protein Induces Antigen-specific T Cell Activation <i>in vitro</i> and <i>in vivo</i> , <i>Cellular Immunology</i> 192(1):54-62 (1999).
	7 ✓	Endoh, et al., Studies of Experimental Allergic Encephalomyelitis in Old Mice, <i>J. of Neuroimmunol.</i> , 29:21-31 (1990).
	8 ✓	Gosselin, et al., Enhanced Antigen Presentation Using Human Fc γ Receptor (Monocyte/Macrophage)-Specific Immunogens, <i>J. Immunol.</i> , 149(11):3477-3481 (1992).
	9 ✓	Muller, et al., Selective <i>in vivo</i> Inhibition of T Cell Activation by Class II MHC-Binding Peptides Administered in Soluble Form, <i>J. Immunol.</i> , 145(12):4006-4011 (1990).
	10 ✓	Riechmann, et al., Reshaping human antibodies for therapy, <i>Nature</i> , Vol. 332, March 24: 323-327 (1988).
	11 ✓	Sollazzo, et al., Expression of an exogenous peptide epitope genetically engineered in the variable domain of an immunoglobulin: implications for antibody and peptide folding, <i>Protein Engineering</i> , Vol. 4, No. 2: 215-220 (1990).
	12 ✓	Takemori, et al., Mechanism of Neonatally Induced Idiotype Suppression and its Relevance for the Acquisition of Self-tolerance, <i>Immunological Reviews</i> , 79:103-117.
	13 ✓	Zaghouani, et al., Engineered Immunoglobulin Molecules as Vehicles for T Cell Epitopes, <i>Intern. Rev. Immunol.</i> , 10: 265-278 (1993).
	14 ✓	Zaghouani, Habib, U.S. App. No. 10/000,868, filed 11/30/01, entitled "Compounds, Compositions and Methods for the Endocytic Presentation of Immunosuppressive Factors," Docket No. ALLIA.143DV1.
PN	15	International Search Report for co-pending Application No. PCT/US01/40834.

S:\DOCS\SGJ\SGJ-1415.DOC:dmbr
012202

EXAMINER	<i>PN</i>	DATE CONSIDERED	<i>6/28/04</i>
*EXAMINER: INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.			